Chinese Herbal Medicine in the Treatment of Chronic Kidney Disease

2005 ◽  
Vol 12 (3) ◽  
pp. 276-281 ◽  
Author(s):  
Xiaomei Li ◽  
Haiyan Wang
2021 ◽  
Vol 12 ◽  
Author(s):  
Yan-Zhuan Xiao ◽  
Zhi-Zhong Ye ◽  
Yuan-Tong Liang ◽  
Xin-Peng Chen ◽  
Yu-Hsun Wang ◽  
...  

Background: Chinese herbal medicine (CHM) has been nationally and globally used in treating gout for over a millennium. The potential relationship between the incidence of chronic kidney disease (CKD) in gout patients and CHM therapy is unclear. Thus, this study aimed to provide some evidence regarding the relationship between CHM therapy and the occurrence of CKD in gout patients.Methods: We used data from the National Health Insurance Research database (NHIRD) in Taiwan. In this population-based nested case-control study, all participants were identified by International Classification of Diseases, Ninth Revision (ICD-9). Conditional logistic regression was used to calculate the odds ratio (OR) of the risk of CKD in gout patients treated with CHM therapy.Results: Data on 1718 gout patients with CKD and 1:1 matched 1718 gout patients without CKD were collected for analysis. The results showed that CHM therapy in gout patients did not increase the risk of developing CKD (adjusted OR = 1.01; 95% confidence interval [CI]: 0.86–1.18; p > 0.05). Moreover, CHM therapy in gout patients for >365 days did not increase the incidence of CKD (adjusted OR = 1.30; 95% CI: 0.90–1.88; p = 0.162).Conclusion: Traditional CHM therapy does not increase the incidence of CKD in gout patients.


2015 ◽  
Vol 88 (6) ◽  
pp. 1365-1373 ◽  
Author(s):  
Ming-Yen Lin ◽  
Yi-Wen Chiu ◽  
Jung-San Chang ◽  
Hung-Lung Lin ◽  
Charles Tzu-Chi Lee ◽  
...  

2012 ◽  
Vol 55 (2) ◽  
pp. 155-159 ◽  
Author(s):  
Chuan-Fa Hsieh ◽  
Song-Lih Huang ◽  
Chien-Lung Chen ◽  
Wei-Ta Chen ◽  
Huan-Cheng Chang ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-14
Author(s):  
Zhenzhen Lu ◽  
Yifei Zhong ◽  
Wangyi Liu ◽  
Ling Xiang ◽  
Yueyi Deng

Diabetic kidney disease (DKD) is the most common microvascular complication of diabetes and is one of the main causes of end-stage renal disease (ESRD) in many countries. The pathological features of DKD are the hypertrophy of mesangial cells, apoptosis of podocytes, glomerular basement membrane (GBM) thickening, accumulation of extracellular matrix (ECM), glomerular sclerosis, and tubulointerstitial fibrosis. The etiology of DKD is very complicated and many factors are involved, such as genetic factors, hyperglycemia, hypertension, hyperlipidemia, abnormalities of renal hemodynamics, and metabolism of vasoactive substances. Although some achievements have been made in the exploration of the pathogenesis of DKD, the currently available clinical treatment methods are still not completely effective in preventing the progress of DKD to ESRD. CHM composed of natural products has traditionally been used for symptom relief, which may offer new insights into therapeutic development of DKD. We will summarize the progress of Chinese herbal medicine (CHM) in the treatment of DKD from two aspects. In clinical trials, the Chinese herbal formulas were efficacy and safety confirmed by the randomized controlled trials. In terms of experimental research, studies provided evidence for the efficacy of CHM from the perspectives of balancing metabolic disorders, reducing inflammatory response and oxidative stress, antifibrosis, protecting renal innate cells, and regulating microRNA and metabolism. CHM consisting of different ingredients may play a role in synergistic interactions and multiple target points in the treatment of DKD.


2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Yuyang Wang ◽  
Hailing Zhao ◽  
Qian Wang ◽  
Xuefeng Zhou ◽  
Xiaoguang Lu ◽  
...  

Diabetic kidney disease (DKD), a leading cause of end-stage renal disease (ESRD), has become a serious public health problem worldwide and lacks effective therapies due to its complex pathogenesis. Recent studies suggested defective autophagy involved in the pathogenesis and progression of DKD. Chinese herbal medicine, as an emerging option for the treatment of DKD, could improve diabetic kidney injury by activating autophagy. In this review, we briefly summarize underlying mechanisms of autophagy dysregulation in DKD, including AMP-activated protein kinase (AMPK), the mechanistic target of rapamycin (mTOR), and the sirtuin (Sirt) pathways, and we particularly concentrate on the current status of Chinese herbal medicine treating DKD by regulating autophagy. The advances in our understanding regarding the treatment of DKD via regulating autophagy with Chinese herbal medicine will enhance the clinical application of Chinese medicine as well as discovery of novel therapeutic agents for diabetic patients.


Sign in / Sign up

Export Citation Format

Share Document